Consider Adakveo
- Adakveo was studied and approved in HbSS/HbSβᵒ thalassemia (patients with sickle cell anemia)
- It is approved in for patients age 16 years and older
- You should consider Adakveo if any of the following apply to you
- Have 3 or more pain crisis in a 12 month period
- Visit the Emergency room to control pain crisis
- Have had an acute chest syndrome event
- Hospital admit to treat pain crisis
- Take long-acting pain medicine daily
Click to save the above section, so that you may easily reference it later